A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the optimal daily dose and dose regimen of YM150
in subjects with non-valvular atrial fibrillation (NVAF), primarily based on safety and
tolerability data.